| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 1063.1 | 1003.4 | 760.8 |
| Other income | 29.0 | 10.8 | 22.1 |
| Total income | 1092.1 | 1014.2 | 782.9 |
| Profit before exceptional items & tax | 152.7 | 125.4 | 152.1 |
| Exceptional items | 0.0 | -20.3 | 0.0 |
| Profit before tax | 152.7 | 105.1 | 152.1 |
| Net profit | 116.2 | 79.7 | 116.4 |
| Operating margin | 14.0% | 10.4% | 19.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -0.20% |
|---|---|
| Net profit, quarter on quarter | +45.80% |
| Revenue, year on year | +39.70% |
| Operating profit, year on year | -7.50% |
| Operating profit, quarter on quarter | +26.60% |
BSE results filing, NSE: INDGN. Figures extracted from the filing.
Indegene Ltd: key numbers
- Share price
- ₹608.95
- Market cap
- ₹14,670 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 36.6×Sector 57.8×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 9.92%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Business Update
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Merger & Restructuring
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Earnings Call Transcript: Key Takeaways
Indegene delivered its strongest Q1 growth in four years, yet remains burdened by elevated costs from strategic investments and workforce transformation.
Indegene Investor Presentation: Key Takeaways
Indegene reported Q1'FY27 revenue of ₹10,631M (+39.7% YoY) with an EBITDA margin of 16.9%. The strategy focuses on scaling GenAI-powered solutions and deepening engagement with large pharma.
Indegene Earnings Call: Key Takeaways
Indegene reported FY26 revenue of INR 35,105M with 19.4% adjusted EBITDA margin, positioning itself as an AI-embedded specialist displacing traditional agencies and CROs in life sciences.
Indegene Earnings Call: Key Takeaways
Indegene positions as an AI-embedded operating partner for life sciences. Reported FY26 revenue of INR 35.1Bn with 19.4% EBITDA margins and 29.4% CAGR.